In case MSN launches the generic version of the drug in July 2025, Divi’s Laboratories’ estimated earnings from Entresto API could be ₹700 crore in FY26. If the MSN launch is delayed, Divi’s can make around ₹1,000 crore to ₹1,200 crore in FY26.
In case MSN launches the generic version of the drug in July 2025, Divi’s Laboratories’ estimated earnings from Entresto API could be ₹700 crore in FY26. If the MSN launch is delayed, Divi’s can make around ₹1,000 crore to ₹1,200 crore in FY26.